Suppr超能文献

吸入性皮质类固醇不能预防对沙美特罗支气管保护作用产生耐受性。

Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol.

作者信息

Kalra S, Swystun V A, Bhagat R, Cockcroft D W

机构信息

Division of Respiratory Medicine, Royal University Hospital, University of Saskatchewan, Saskatoon, Canada.

出版信息

Chest. 1996 Apr;109(4):953-6. doi: 10.1378/chest.109.4.953.

Abstract

INTRODUCTION

Twice-daily inhaled salmeterol produces rapid reduction in its acute bronchoprotective effect against methacholine in patients with mild asthma. This investigation examined this effect in patients with moderate asthma who were using inhaled corticosteroids.

SUBJECTS AND METHODS

Eight asthmatic volunteers who required inhaled corticosteroids for control of their symptoms and who were able to withhold treatment with beta 2-agonists for 4 weeks before and during the study participated in a double-blind, crossover, placebo-controlled study with two random-order treatment periods: inhaled salmeterol, 50 microg twice a day for seven doses, and placebo in similar fashion, with a 7-day or greater washout between these periods. Methacholine inhalation tests were done 1 h after doses 1, 3, 5, and 7, and then 24 h after the last dose of the study inhaler, 10 min post-200 microg salbutamol.

RESULTS

Baseline FEV1 measurements before doses 3, 5, and 7 of salmeterol, ie, 12 h after salmeterol, were significantly higher than all other baseline values. Twenty-four hours after the last dose of salmeterol, the FEV1 was no different from that during the placebo period. The geometric mean methacholine concentration causing a 20% fall in FEV1 (PC20) following the third dose of salmeterol (6.8 mg/mL) was significantly lower than after the first dose of salmeterol (12.0 mg/mL; p=0.031), and this reduction of bronchoprotection persisted following doses 5 and 7. The methacholine PC20 10 min postsalbutamol measured after the salmeterol period was significantly lower than after placebo (5.6 vs 13.3 mg/mL; p<0.001).

CONCLUSIONS

Tolerance to the acute bronchoprotective effect of salmeterol was significant after the first two doses and persisted after the seventh dose. Tolerance to the acute bronchoprotective effect of salbutamol was also significant after regular use of salmeterol for seven doses. These effects, in subjects using inhaled corticosteroids regularly, were similar to the those previously seen in patients with mild asthma using as-required beta 2-agonists only, indicating that tolerance is not prevented by use of inhaled corticosteroids.

摘要

引言

对于轻度哮喘患者,每日两次吸入沙美特罗可使其对乙酰甲胆碱的急性支气管保护作用迅速降低。本研究在使用吸入性糖皮质激素的中度哮喘患者中考察了这一效应。

受试者与方法

八名哮喘志愿者参与了一项双盲、交叉、安慰剂对照研究,该研究有两个随机顺序的治疗阶段。这些志愿者需要使用吸入性糖皮质激素来控制症状,并且在研究前和研究期间能够停用β2激动剂4周。治疗阶段分别为:每日两次吸入50微克沙美特罗,共七剂,以及以类似方式使用安慰剂,两个阶段之间有7天或更长的洗脱期。在第1、3、5和7剂给药后1小时进行乙酰甲胆碱吸入试验,然后在研究吸入器最后一剂给药后24小时、200微克沙丁胺醇给药后10分钟进行试验。

结果

在沙美特罗第3、5和7剂给药前,即沙美特罗给药12小时后的基线FEV1测量值显著高于所有其他基线值。沙美特罗最后一剂给药24小时后,FEV1与安慰剂阶段无差异。第三剂沙美特罗(6.8毫克/毫升)后导致FEV1下降20%的乙酰甲胆碱浓度几何平均值(PC20)显著低于第一剂沙美特罗后(12.0毫克/毫升;p=0.031),并且在第5和7剂给药后这种支气管保护作用的降低持续存在。沙美特罗阶段后沙丁胺醇给药10分钟时测量的乙酰甲胆碱PC20显著低于安慰剂后(5.6对13.3毫克/毫升;p<0.001)。

结论

在前两剂后,对沙美特罗急性支气管保护作用的耐受性显著,且在第七剂后仍持续存在。在规律使用沙美特罗七剂后,对沙丁胺醇急性支气管保护作用的耐受性也显著。在经常使用吸入性糖皮质激素的受试者中,这些效应与之前仅按需使用β2激动剂的轻度哮喘患者中所见的效应相似,表明吸入性糖皮质激素的使用并不能防止耐受性的产生。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验